Eva Wikström Jonsson
Karolinska University Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Eva Wikström Jonsson.
Journal of Asthma | 2006
Marianne Heibert Arnlind; Mika Nokela; Clas Rehnberg; Eva Wikström Jonsson
The objective of this study is to explore the relationship between variables that may influence pharmaceutical costs in asthma and to generate a predictive model for these costs in primary health care. The understanding of these relationships is important since costs of drugs may place unnecessary economic burden on patients and society. During 2003, prospective clinical data were collected from 105 patients in 24 primary health care centers located in Stockholm. The relationships between cost of drugs and quality of life, lung function, and asthma severity were analyzed in a regression model. Twenty-three percent of the observed variation in pharmaceutical costs could be explained by asthma severity, disease-specific quality of life, and clinical practice. There was a weak inverse correlation between pharmaceutical costs, generic quality of life, and lung function. Even when severity was accounted for, there were large variations in costs between different primary health care units.
Respiration | 2010
Mika Nokela; Marianne Heibert Arnlind; Per-Olof Ehrs; Ingvar Krakau; Lennart Forslund; Eva Wikström Jonsson
Background: In clinical trials of asthma, the outcomes are often good, but when the same treatment regimens are implemented in primary care, equally good results are not obtained. Objective: To investigate if addition of structured patient information and monitoring by an asthma diary in primary care improves asthma control. Methods: 141 patients from 19 primary care centres were studied. The centres were randomised to a standard care group or to an intervention group. The intervention group received structured written and oral information about asthma and asthma medication, and were instructed to keep an asthma diary. The primary outcome was asthma control as assessed by the Asthma Control Questionnaire. Secondary outcomes were costs of asthma medication, the Mini Asthma Quality of Life Questionnaire score and lung function. Results: Asthma Control Questionnaire score changes differed between the study groups (p < 0.05). In the intervention group, these changes (M = –0.45) in asthma control were close to clinical significance (minimal important difference ≈0.5). Both groups improved in disease-specific quality of life scores. For the intervention group, which changed the most (p < 0.05), the change exceeded the threshold for the minimal important difference (0.5). The costs of medications increased significantly in the intervention group, where adjustments of medication were made more often than in controls. Conclusion: Disease-specific quality of life of asthma patients could be improved by adding structured information and monitoring by diary to standard care.
Journal of Asthma | 2013
Marianne Heibert Arnlind; Björn Wettermark; Bengt Sjöborg; Elin Dahlén; Desirée Loikas; Eva Wikström Jonsson
Abstract Introduction: Socioeconomic status (SES) is strongly associated with morbidity as well as with health care utilization and expenditure. The association between SES and quality of prescribing of asthma drugs is less studied. Objectives: The aim of this study was to examine the association between socioeconomic factors, i.e. education, income and country of birth, and the prevalence, incidence and adherence to guidelines for antiasthmatic drugs. Methods: This registry study includes all Swedish citizens aged 25–44 years who redeemed at least one prescription of an antiasthmatic drug during 2010. Incidence and prevalence was calculated. The adherence to guidelines was studied using two defined quality indicators. Heavy users were also assessed. Results: Incidence for antiasthmatic drugs was 18.4 per 1000 person-years and the prevalence 50.9 per 1000 inhabitants. Previously untreated patients who redeemed fixed combination ranged from 45% to 49%. Patients who purchase long-acting beta-2-adrenoceptor agonists (LABA) without inhaled corticosteroid ranged from 43% to 59%. Six percent of the population was classified as heavy users. Conclusion: The study showed a high incidence and prevalence of asthma drug use with a poor adherence to guidelines for rational drug prescribing. Fixed combination as first line asthma treatment as well as purchasing LABA without concomitant ICS was more common in patients born outside Scandinavia. Heavy users of short-acting bronchodilators were associated with male sex, high age, low income levels and low levels of education.
Chest | 2006
Per-Olof Ehrs; Mika Nokela; Björn Ställberg; Paul Hjemdahl; Eva Wikström Jonsson
Health and Quality of Life Outcomes | 2009
Björn Ställberg; Mika Nokela; Per-Olof Ehrs; Paul Hjemdal; Eva Wikström Jonsson
European Journal of Clinical Pharmacology | 2010
Marianne Heibert Arnlind; Björn Wettermark; Mika Nokela; Paul Hjemdahl; Clas Rehnberg; Eva Wikström Jonsson
European Journal of Pharmacology | 1996
Magnus Bäck; Eva Wikström Jonsson; Sven-Erik Dahlén
European Journal of Pharmacology | 1998
Eva Wikström Jonsson; Urban Rosenqvist; Sven-Erik Dahlén
Quality in primary care | 2012
Maria Ingemansson; Björn Wettermark; Eva Wikström Jonsson; Bredgard M; Marina Jonsson; Gunilla Hedlin; Anna Kiessling
Prostaglandins, Laukotrienes and Other Eicosanoids: From Biogenesis to Clinical Application | 2007
Eva Wikström Jonsson; Sven-Erik Dahlén